The complement pathway has been proposed as a therapeutic target for Alzheimer’s disease (AD). Pharmacologic inhibition of C5aR1 suppresses disease-enhancing processes and promotes disease mitigating pathways in an aggressive model of AD.
- Nicole D. Schartz
- Heidi Y. Liang
- Andrea J. Tenner